Pulmonary epithelial markers in phenotypes of chronic lung allograft dysfunction

被引:3
|
作者
Levy, Liran [1 ,2 ]
Moshkelgosha, Sajad [1 ]
Huszti, Ella [3 ,4 ]
Hunter, Sarah [1 ]
Renaud-Picard, Benjamin [1 ]
Berra, Gregory [1 ]
Kawashima, Mitsuaki [1 ]
Fernandez-Castillo, Juan [1 ]
Fuchs, Eyal [1 ]
Dianti, Milagros [1 ]
Ghany, Rasheed [1 ]
Keshavjee, Shaf [1 ,4 ]
Singer, Lianne G. [1 ,4 ]
Tikkanen, Jussi [1 ]
Martinu, Tereza [1 ,4 ,5 ]
机构
[1] Univ Hlth Network, Toronto Lung Transplant Program, Toronto, ON, Canada
[2] Tel Aviv Univ, Inst Pulm Med, Sackler Fac Med, Sheba Med Ctr, Tel Aviv, Israel
[3] Univ Hlth Network, Biostat Res Unit, Toronto, ON, Canada
[4] Univ Toronto, Toronto, ON, Canada
[5] Toronto Gen Hosp, 585 Univ Ave, PMB 11-128, Toronto, ON M5G 2N2, Canada
来源
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2023年 / 42卷 / 08期
基金
加拿大健康研究院;
关键词
lung transplant; chronic lung allograft dysfunction phenotypes; restrictive allograft syndrome; mixed phenotype; bronchiolitis obliterans syndrome; epithelial cell death; BRONCHIOLITIS OBLITERANS SYNDROME; SURFACTANT PROTEIN-A; PROGNOSTIC VALUE; AIRWAY MUCUS; SERUM; KL-6; TRANSPLANTATION; CA-125; FLUID; TRANSITION;
D O I
10.1016/j.healun.2023.03.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Airway epithelial injury is thought to be a key event in the pathogenesis of chronic lung allograft dysfunction (CLAD). We investigated whether markers of epithelial activity and injury in bronchoalveolar lavage fluid (BAL) correlate with CLAD diagnosis and major CLAD phenotypes: bronchiolitis obliterans syndrome (BOS) vs restrictive allograft syndrome (RAS)-related phenotypes (including RAS, mixed phenotype, and all other patients with RAS-like opacities).METHODS: CLAD status and phenotypes were retrospectively determined in a cohort of all consecutive adult, first, bilateral lung transplants performed 2010-2015, with available BAL samples. All patients with RAS-related phenotypes were included and 1:1 matched with BOS patients based on the time from transplant to CLAD-onset. Subjects who were CLAD-free for a minimum of 3 years post -transplant were 1:1 matched to CLAD patients and included as controls. Proteins that maintain the barrier function of the airway epithelial mucosa (club cell secretory protein, surfactant protein-D and epithelial mucins: MUC1, MUC5AC, MUC5B, MUC16), as well as epithelial cell death markers (M30 & M65 representing epithelial cell apoptosis and overall death, respectively), were measured in BAL obtained within 6-months post CLAD onset using a double-sandwich ELISA or a multiplex bead assay. Protein levels were compared using Mann-Whitney-U-test. Association between protein levels and graft survival was assessed using Cox proportional hazards models, adjusted for CMV serology mismatch status and CLAD phenotype.RESULTS: Fifty-four CLAD (27 BOS, 11 RAS, 7 mixed, 9 others with RAS-like opacities) patients and 23 CLAD-free controls were included. Median BAL levels were significantly higher in patients with CLAD compared to CLAD-free controls for M30 (124.5 vs 88.7 U/L), MUC1 (6.8 vs 3.2 pg/mL), and MUC16 (121.0 vs 30.1 pg/mL). When comparing CLAD phenotypes, M30 was significantly higher in patients with RAS-related phenotypes than BOS (160.9 vs 114.6 U/L). In multivariable models, higher M30 and MUC5B levels were associated with decreased allograft survival after CLAD onset independent of phenotype (p < 0.05 for all).CONCLUSIONS: Airway epithelial mucins and cell death markers are enhanced in the BAL of patients with CLAD and can assist in differentiating between CLAD phenotypes and post-CLAD outcomes. Abnormal airway mucin expression and epithelial cell death may be involved in the pathogenesis of CLAD, and therefore their detection may aid in future selection of targeted therapies. J Heart Lung Transplant 2023;42:1152-1160 & COPY; 2023 International Society for Heart and Lung Transplantation. All rights reserved.
引用
收藏
页码:1152 / 1160
页数:9
相关论文
共 50 条
  • [1] Pulmonary Markers of Epithelial Cell Activation and Injury in Chronic Lung Allograft Dysfunction
    Levy, L.
    Moshkelgosha, S.
    Huszti, E.
    Hunter, S.
    Renaud-Picard, B.
    Berra, G.
    Kawashima, M.
    Takahagi, A.
    Fernandez-Castillo, J.
    Fuchs, E.
    Ghany, R.
    Keshavjee, S.
    Singer, L.
    Tikkanen, J.
    Martinu, T.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S163 - S163
  • [2] Pulmonary Markers of Epithelial Cell Activity and Injury in Chronic Lung Allograft Dysfunction
    Levy, L.
    Moshkelgosha, S.
    Huszti, E.
    Hunter, S.
    Renaud-Picard, B.
    Berra, G.
    Kawashima, M.
    Takahagi, A.
    Fernandez-Castillo, J.
    Fuchs, E.
    Keshavjee, S.
    Singer, L.
    Tikkanen, J.
    Martinu, T.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S56 - S56
  • [3] Epithelial Cell Death Markers in Bronchoalveolar Lavage Correlate with Chronic Lung Allograft Dysfunction Phenotypes
    Levy, L.
    Tigert, A.
    Moshkelgosha, S.
    Joe, B.
    Boonstra, K.
    Saito, T.
    Tikkanen, J.
    Keshavjee, S.
    Juvet, S.
    Martinu, T.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S215 - S215
  • [4] PHENOTYPES IN CHRONIC LUNG ALLOGRAFT DYSFUNCTION
    Auner, Sophia
    Berezhinskiy, Hatice Oya
    Boehm, Panja M.
    Morscher, Annika
    Schwarz, Stefan
    Frick, Anna E.
    Schweiger, Thomas
    Hoda, Alireza Mir
    Moser, Bernhard
    Matilla, Jose Ramon
    Murakozy, Gabriela
    Lang, Gyoergy
    Taghavi, Shahrokh
    Klepetko, Walter
    Hoetzenecker, Konrad
    Jaksch, Peter
    Benazzo, Alberto
    TRANSPLANT INTERNATIONAL, 2021, 34 : 17 - 17
  • [5] Chronic lung allograft dysfunction phenotypes and treatment
    Verleden, Stijn E.
    Vos, Robin
    Vanaudenaerde, Bart M.
    Verleden, Geert M.
    JOURNAL OF THORACIC DISEASE, 2017, 9 (08) : 2650 - 2659
  • [6] Changing the curve in chronic lung allograft dysfunction: Implications of chronic lung allograft dysfunction phenotypes in assessing treatment interventions
    Mooney, Joshua J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (03): : 319 - 320
  • [7] Mechanistical differences of chronic lung allograft dysfunction phenotypes in lung transplantation
    Suwara, Monika I.
    Vanaudenaerde, Bart M.
    Verleden, Stijn E.
    Borthwick, Lee A.
    Vos, Robin
    Green, Nicola J.
    Ward, Chris
    Van Raemdonck, Dirk E.
    Corris, Paul A.
    Mann, Derek A.
    Verleden, Geert M.
    Fisher, Andrew J.
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [8] Chronic lung allograft dysfunction and restrictive allograft syndrome: are phenotypes robust and helpful?
    Verleden, Geert M.
    Godinas, Laurent
    Vos, Robin
    Verleden, Stijn E.
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2022, 27 (03) : 211 - 216
  • [9] Characterization of chronic lung allograft dysfunction phenotypes using oscillometry
    Fu, A.
    Vasileva, A.
    Hanafi, N.
    Belousova, N.
    Wu, J.
    Rajyam, S. S.
    Hantos, Z.
    Chow, C.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [10] Prevalence and Prognosis of Updated Phenotypes of Chronic Lung Allograft Dysfunction
    Combs, M. P.
    Wheeler, D. S.
    Belloli, E. A.
    Jia, S.
    Lyu, D. M.
    Chan, K. M.
    Lama, V. N.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S162 - S163